Holen Sie sich die Stockscreener-App
3.25
8.70%
0.26
Handel nachbörslich:
3.23
-0.02
-0.62%
Schlusskurs vom Vortag:
$2.99
Offen:
$3.13
24-Stunden-Volumen:
768.08K
Relative Volume:
0.64
Marktkapitalisierung:
$183.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.44M
KGV:
-1.4254
EPS:
-2.28
Netto-Cashflow:
$-66.75M
1W Leistung:
+13.64%
1M Leistung:
-13.33%
6M Leistung:
-53.30%
1J Leistung:
+71.05%
1-Tages-Spanne:
$3.04
$3.37
1-Wochen-Bereich:
$2.735
$3.37
52-Wochen-Spanne:
$1.62
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Firmenname
Black Diamond Therapeutics Inc
Sektor
Branche
Telefon
617-417-5868
Adresse
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-31 | Eingeleitet | Raymond James | Outperform |
| 2023-07-14 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-30 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-03-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-03-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-01-07 | Eingeleitet | Wedbush | Outperform |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-02-24 | Eingeleitet | Cowen | Outperform |
| 2020-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle
BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat
Black Diamond Therapeutics Inc (BDTX) looking to reclaim success with recent performance - SETE News
Investing in Black Diamond Therapeutics Inc (BDTX) Is Getting More Attractive - Knox Daily
Results from Black Diamond Therapeutics Inc (BDTX) show potential - US Post News
Market Update: Black Diamond Therapeutics Inc (BDTX) Sees Negative Movement, Closing at 3.33 - The Dwinnex
Dimensional Fund Advisors LP Has $932,000 Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87 - Knox Daily
FY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by Analyst - MarketBeat
Analysts’ Recent Ratings Changes for Black Diamond Therapeutics (BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) is looking forward to a strong quarter - SETE News
Cuts for Black Diamond as runway's end nears - The Pharma Letter
Q3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Issued By Wedbush - MarketBeat
Layoffs at local cancer drug developer; Flagship names new managing partner - The Business Journals
Black Diamond Therapeutics (NASDAQ:BDTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data (BDTX) - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway - Investing.com India
Black Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at Wedbush - MarketBeat
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares - Investing.com Canada
Black Diamond Therapeutics Inc (BDTX) Becoming More Attractive for Investors - Knox Daily
Black Diamond Therapeutics Inc (BDTX) stock analysis: A simple moving average approach - US Post News
Market Highlights: Black Diamond Therapeutics Inc (BDTX) Ends on a Low Note at 3.66 - The Dwinnex
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - ForexTV.com
Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program - TipRanks
Black Diamond Therapeutics to Cut Jobs Amid Restructuring, Names New CFO - MarketWatch
Black Diamond CFO departs as part of restructuring, job cuts - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway By Investing.com - Investing.com Canada
Black Diamond Therapeutics Announces Restructuring Plan to - GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - GlobeNewswire Inc.
Black Diamond Therapeutics Inc [NASDAQ: BDTX] Sees Decrease in Stock Value - Knox Daily
Black Diamond Therapeutics Inc (BDTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
It is Poised to be a Bull Market for Black Diamond Therapeutics Inc (BDTX) - SETE News
Analyzing Black Diamond Therapeutics Inc (BDTX) After Recent Trading Activity - Knox Daily
Stock Surge: Black Diamond Therapeutics Inc (BDTX) Closes at 4.23, Marking a -4.08 Increase/Decrease - The Dwinnex
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - US Post News
A company insider recently sold 221,600 shares of Black Diamond Therapeutics Inc [BDTX]. Should You Sale? - Knox Daily
A look into Black Diamond Therapeutics Inc (BDTX)’s deeper side - SETE News
Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BlackGold Secures Critical Extension for Proposal - TipRanks
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wave claims early lead in second-generation exon 53 skipping - BioCentury
Black Diamond Therapeutics Inc (BDTX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Black Diamond Therapeutics (NASDAQ:BDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Black Diamond shares hold buy rating on Phase 2 results - Investing.com India
BlackLine ticks higher as board appointment stokes some takeover speculation - Seeking Alpha
Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):